Reconciliation of Selected GAAP Measures to Non-GAAP Measures
(In thousands, except per share amounts)
26 Please note that the figures presented may not sum exactly due to rounding
Alnylam Pharmaceuticals, Inc.
Reconciliation of Revenue and Growth at Constant Currency
Please note that the figures presented may not sum exactly due to rounding
27 Constant Currency = Constant Exchange Rate, or CER
Attachments
Original Link
Original Document
Permalink
Disclaimer
Alnylam Pharmaceuticals Inc. published this content on
02 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
02 May 2024 12:58:18 UTC.
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.